High-dose therapy and hematopoietic stem cell transplantation (HSCT) have been shown to improve survival rates in high-risk neuroblastoma (HR-NBL), but may cause adverse effects on the growing skeleton. We studied skeletal health in a national cohort of long-term survivors of HR-NBL (n = 21; age 16-30 years, median 22 years) and in 20 healthy age-and sex-matched controls. In addition to clinical evaluation and measurement of bone mineral density (BMD) by dual-energy X-ray absorptiometry, we performed spinal magnetic resonance imaging. Skeletal complications were categorized according to Common Terminology Criteria for Adverse Events (CTCAE). Altogether, 18/21 survivors presented with at least one skeletal adverse event according to CTCAE, the most common skeletal complications being short stature (n = 14) and osteopenia (n = 13). Altogether, 38% of the subjects had a severe complication (CTCAE score ⩾ 3) including bilateral slipped capital femoral epiphyseolysis in 3/21. Fracture rate was not increased. In spinal MRI, no vertebral fractures were found and degenerative intervertebral disc changes were equally prevalent in survivors and controls. BMD was lower in survivors than controls, but differences became non-significant when adjusted for bone size. In conclusion, skeletal late complications are common and can significantly impair the quality of life in young adult survivors of HR-NBL treated with high-dose protocols and HSCT.
INTRODUCTION
Neuroblastoma (NBL) is the most common extracranial solid cancer in children. More than half of the patients have high-risk neuroblastoma (HR-NBL), referring to either disseminated (stage 4) or advanced (stage 2-3) disease with MycN amplification, in which the prognosis has remained unfavorable. 1, 2 However, with multimodal treatment including intensive induction chemotherapy, high-dose therapy and autologous hematopoietic stem cell transplantation (HSCT), the long-term survival rate is increasing. Currently, chemotherapy-based regimens have replaced TBI as a highdose modality before HSCT, but local irradiation is still used.
Cancer treatment in childhood can cause adverse skeletal effects. In childhood ALL, where glucocorticoids are an integral part of the treatment, low bone mineral density (BMD) and altered bone metabolism are well documented at diagnosis and during the treatment, although evidence for a long-term BMD deficit remains inconsistent. 3, 4 Less is known about BMD in childhood solid cancer, but some studies report BMD decrement in mixed groups of different cancers during or after treatment. [5] [6] [7] [8] Only one study evaluated BMD separately in NBL patients, showing decreased BMD at diagnosis. 9 In child ALL patients, fracture frequency is increased during and shortly after the treatment. [10] [11] [12] Although BMD deficit is a well-recognized complication after childhood cancer, surprisingly little is known about spinal fractures and other spinal abnormalities. A large childhood ALL study showed, by systematic radiographic screening, a cumulative vertebral fracture incidence of 26.4% during the first 4 years after diagnosis. 13 In children with severe juvenile arthritis, treated with high-dose glucocorticoids, magnetic resonance imaging (MRI) showed a high prevalence of not only compression fractures but also other disc abnormalities in the thoracic and lumbar spine. 14 To our knowledge, spinal structures have not been systematically evaluated by MRI in childhood cancer survivors.
Skeletal problems after childhood cancer may also include short stature, spinal malalignments (scoliosis, kyphosis), limb length discrepancy, osteonecrosis and osteochondromas. 15 In a recent large cohort study, musculoskeletal complications were among the most common adverse health events after childhood allogeneic HSCT. 16 Long-term skeletal consequences of childhood autologous HSCT remain largely unknown.
No previous studies have evaluated detailed skeletal outcome after childhood HR-NBL. As the patients are exposed to aggressive treatment at a young age, they may be especially susceptible to adverse skeletal effects. We investigated skeletal health in a national cohort of long-term HR-NBL survivors treated with high-dose therapy and HSCT. In addition to evaluation of BMD and fracture rate, we performed spinal MRI to gain knowledge on the late effects on vertebrae and intervertebral discs.
SUBJECTS AND METHODS

Study population
A national cohort of long-term (410 years) survivors of HR-NBL treated at the University Hospitals in Finland between 1980 and 2000 were invited to participate in this follow-up study. One survivor of HR retinoblastoma treated on the HR-NBL protocol was also included. Of the identified 24 long-term survivors, 21 (88%) consented and 19/21 completed the study, whereas only partial data were obtained for 2/21 subjects. The clinical and treatment characteristics of the enrolled cohort 17 and the outcome of the patients treated at Helsinki University Hospital 18, 19 have been previously published. All consented survivors had been treated with HSCT, and 3/21 with tandem HSCTs. Eleven survivors had received TBI before HSCT; HSCT was followed by local radiotherapy in 15/21. Three subjects had spinal infiltration at diagnosis (Table 1) . Median follow-up time was 20 years (range [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] .
The control group comprised 20 healthy, age-and sex-matched paired controls. Informed consent was received from all subjects. The institutional review board approved the study, and it was carried out in accordance with the Declaration of Helsinki.
Clinical and laboratory evaluations
All subjects had physical examination by the same physician (AV). Blood samples for parameters of calcium homeostasis were drawn after an overnight fast between 08.30 and 09.15 h on the examination day. Bone age was evaluated from the left hand radiograph. Data on present and previous skeletal complications, including fractures, were collected with a questionnaire and interview, from hospital records, and by physical examination. In the HR-NBL survivors, skeletal complications were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Adverse skeletal events that could not explicitly be found in the CTCAE criteria were graded as follows: grade 1, mild, clinically unremarkable changes, detected by diagnostic methods; grade 2, moderate abnormalities needing further intervention (for example, follow-up, physiotherapy) or mild symptoms not interfering with daily life; grade 3, skeletal late complications needing more aggressive treatment, for example, surgery.
Bone mineral density BMD was analyzed by dual-energy X-ray absorptiometry (DXA) in 19 survivors and 20 control subjects for whole body, left total hip (LH), left femoral neck (FN) and lumbar spine (LS) (Hologic Discovery A, Bedford, MA, USA, software version 12.3:3). BMD is reported in age-and sex-adjusted Z-scores. To better estimate the true volumetric bone density, 'apparent volumetric bone density' (BMAD) was calculated for LS using the formula developed by Carter et al. 20 'Low BMD' was defined as a BMD Z-score ⩽ − 2.0 at any measured site. 21 However, when evaluating the total burden of skeletal complications according to CTCAE, we used the following CTCAE criteria to define decreased BMD: 'osteopenia' (BMD Z-score o − 1.0) and 'osteoporosis' (BMD Z-score o − 2.5).
Spinal MRI MRI studies were performed to obtain information on vertebral morphology, endplates and intervertebral discs. The same 1.5T imager (Philips Intera Achieva, Philips Medical Systems, Best, The Netherlands) was used in all 18 HR-NBL survivors and 20 controls. The study total-spine protocol included imaging of thoracic and lumbar spine with three sagittal and one coronal sequences: (1) sagittal T1-weighted turbo spin-echo (17 slices, TR 500 ms, TE 7. An experienced radiologist (ST-S) assessed all MRI images for spinal anatomy, vertebral shape, vertebral endplate and intervertebral disc abnormalities.
Statistical analyses
Data analyses were performed using IBM SPSS statistical software for Windows, Version 23 (IBM Corp., Armonk, NY, USA). All BMD parameters were normally distributed. Because of the small sample size, the nonparametric Mann-Whitney U-test was used for all group comparisons, and data are presented as median ± interquartile range or range, as appropriate. Fischer's exact test was used to compare binary variables between the study groups and subgroups. Univariate linear models were used to study factors associated with BMD. All statistical analyses were two sided, and P-values of X0.05 were considered significant.
RESULTS
Cohort characteristics
Cohort characteristics and biochemistry are shown in Table 2 . The median age at diagnosis was 1.7 years and at HSCT 2.3 years. Those aged ⩾ 1.7 years (median age) at diagnosis were more often TBI recipients than younger children (8/10 vs 3/11, P = 0.03). Altogether, 9/11 TBI recipients and 1/10 other survivors had been treated with recombinant human growth hormone (rhGH). None of the survivors had had precocious puberty, whereas in 5 of them (4 girls and 1 boy) delayed puberty had been induced by hormonal substitution; all were post-pubertal at the time of the study. Two survivors had undergone kidney transplantation because of renal dysfunction after cancer treatment. HR-NBL survivors and controls were examined at a median age of 22.6 years (range 15.6-30.0). At the time of examination, 4/8 male survivors were on testosterone and 10/11 female survivors on estrogen substitution. Survivors had lower serum phosphate concentrations, but other laboratory parameters were comparable with the controls (Table 2) .
HR-NBL survivors were significantly shorter and lighter than the controls, whereas bone mass index showed a trend towards lower values in survivors (Tables 2 and 3 ). In the subgroup analyses, TBI recipients tended to be shorter than other survivors (−3.1 vs − 1.9 SD score (SDS), P = 0.24), but both TBI recipients and the non-TBI survivors were significantly shorter than the controls (−3.1 vs +0.2 SDS and − 1.9 vs +0.2 SDS, P o 0.001 for both). There was no difference in height SDS between the survivors with a history of induced puberty and other survivors (−2.8 vs − 2.5, P = 0.67). Bone age evaluation showed completed epiphyseal fusion in all subjects.
Fractures and other skeletal complications according to CTCAE criteria Altogether, 3/21 (14%) survivors of HR-NBL and 2/20 (10%) controls had experienced at least one fracture by young adulthood (P = 1.0), with total numbers of fractures 5 and 4, respectively. Skeletal adverse events (AEs) are described in Table 1 and summarized according to the CTCAE in Table 4 . Altogether, 18/21 (86%) of the survivors had at least one skeletal AE by CTCAE criteria. The most common skeletal AEs were 'short stature' (height Z-score o − 2.0) in 14/21 and 'osteopenia' (BMD Z-score o − 1.0) in 13/21 survivors. Out of the 18 affected, 12 (57%) also had skeletal AEs other than 'short stature' or 'osteopenia'. The most common severe complication was bilateral slipped capital femoral epiphysis (SCFE) in 3 survivors (14%), all needing surgical fixation. The two males with SCFE were on growth hormone (rhGH) substitution at the time of diagnosis; none was overweight. Other skeletal complications included scoliosis/kyphosis (n = 6), exostoses (n = 5) and leg length discrepancy (n = 4). One survivor with a history of kidney transplantation was incidentally found to have osteonecrosis bilaterally in humeri in the spinal MRI. Another survivor had a history of pain in wrists, elbows and knees; retrospective evaluation of her radiographs revealed osteonecrosis bilaterally in radius, ulna, femur and tibia (Tables 1 and 4 ).
In the control group, three had experienced a skeletal problem, one of the following in each of them: exostosis, osteomyelitis and monoarthritis. None had 'short stature', whereas five had 'osteopenia' according to CTCAE, the frequency being significantly smaller than in the survivors (5/20 vs 13/21, P = 0.028).
Among the survivors, TBI recipients tended to have more severe skeletal complications (any skeletal AE of ⩾ 3 CTCAE scores) than non-TBI recipients, although the difference was not statistically significant (6/11 vs 2/10, respectively, P = 0.18). Furthermore, those with both TBI and local irradiation did not show more severe skeletal complications than those with TBI alone (4/7 vs 2/4; P = 1.0), whereas 2/8 of those with local irradiation only also had a severe skeletal complication. There were no differences Skeletal outcome after high-risk neuroblastoma P Utriainen et al in the frequency of severe skeletal complications according to sex (males 4/9 vs females 4/12, P = 0.67) or age at HSCT (age o2.3 years: 4/10 vs age ⩾ 2.3 years: 4/11, P = 1.0). All three survivors with tandem HSCT were short (height Z-score o − 2.5), two of them had a severe skeletal complication by CTCAE, and 1/3 had multiple skeletal complications (patient number 4, Table 1 ).
Bone mineral density BMD Z-scores were lower at whole body, LH and FN in the NBL survivors (n = 19) than controls (n = 20), also separately in male survivors. Among the females, survivors showed lower BMD in the LH (Tables 2 and 3 ). When height Z-score was included in regression analyses, differences in BMD Z-scores between survivors and controls were not significant. LS BMAD was similar between the groups.
'Low BMD' (Z-score o − 2.0) at any site (whole body, LH, FN and LS) was found in 5 survivors but none of the controls (5/19 vs 0/20, P = 0.020). The frequency of 'low BMD' between TBI-and non-TBItreated survivors did not differ (4/10 vs 1/9, P = 0.30). BMD Z-scores did not differ between the survivors with history of pubertal induction (n = 4) and other survivors (n = 15) at any measured site (P = 0.47-0.74), although those with induced puberty showed a trend towards more 'low BMD' (2/4 vs 3/15, P = 0.27).
Among the HR-NBL survivors, height was significantly associated with BMD Z-score at LS (P = 0.003) and LH (P = 0.011) in a univariate linear model including height Z-score, bone mass index and sex. In similar models, none of the factors were significant determinants of BMD Z-score at FN or whole body. When included in the models, neither TBI nor follow-up time were associated with BMD Z-score at any site (P = 0.20-0.88), but serum phosphate associated with BMD Z-score at LH (P = 0.02). In similar models in the controls, only bone mass index independently associated with BMD Z-score at LH and FN (P = 0.008 and P = 0.009, respectively).
Spinal MRI None of the HR-NBL survivors (n = 18) or controls (n = 20) had evidence of vertebral compression fractures on spinal MRI. One survivor had structurally anomalous L1 (hemivertebra) and 3/18 had mildly decreased vertebral height. In the control group, one presented with mildly wedged thoracic vertebrae, associated with degenerative changes in the respective intervertebral discs. Furthermore, two survivors had slightly exaggerated kyphosis and four had mild to severe scoliosis, whereas none of the controls had spinal malalignments. Schmorl's nodules or larger endplate irregularities with signs of disc degeneration were found in 12/18 HR-NBL survivors and 5/18 had mild intervertebral disc protrusion or prolapse. Among the controls, 16/20 had mild degenerative changes in intervertebral discs, 3 with Schmorl's nodules, 9 with a small disc prolapse or protrusion and 2 with consequent endplate changes. Disc degeneration was as prevalent in survivors as in controls (67% vs 80%, P = 0.47). Three controls but none of the survivors had spondylolysis and spondylolisthesis. DISCUSSION This is the first study to describe detailed skeletal outcome in longterm survivors of HR-NBL, and the first to evaluate spinal MRI in any childhood cancer survivors. In our cohort, all survivors were treated with high-dose chemotherapy and autologous HSCT, and half of them also with TBI. The main finding of the present study is that skeletal problems are very common in this patient group already at young adulthood. Altogether, 86% presented with at least one skeletal complication according to CTCAE criteria, the most common of them being 'short stature' and 'osteopenia' (Z-score o − 1.0), both found in almost 2/3 of the survivors.
As reported, 17 our HR-NBL survivors were shorter than their peers at final height, some even extremely short. This indicates a general defect in long-bone growth. The reasons for this include not only direct effects of cancer treatment modalities on growth plates, but also secondary defects in growth hormone and Table 3 . Anthropometric and bone mineral density measurements (median (interquartile range)) according to sex in long-term survivors of HR-NBL (n = 19) and healthy controls (n = 20)
Factor
Case (male n = 8/ female n = 11)
Control (male n = 9/ female n = 11) Abbreviations: BMD = bone mineral density; CTCAE = Common Terminology Criteria for Adverse Events.
Skeletal outcome after high-risk neuroblastoma P Utriainen et al gonadal hormones, and nutritional deficits. We previously showed that a small subgroup of the survivors had low fat mass percentage and low GHbA1c (glycated hemoglobin A1c), indicating poor nutritional status, 22 that may have played a role in the poor growth and other skeletal complications in these subjects. Growth failure after HR-NBL treatment is an acknowledged sequela, also reported in a recent late-effect study, in which all subjects had received TBI as a pretreatment for HSCT. 23 In our cohort, TBI recipients tended to be shorter than other survivors (median height Z-score − 3.1 vs − 1.9), but this difference did not reach statistical significance. Interestingly, even the non-TBItreated survivors were significantly shorter than controls.
Importantly, 57% of survivors also had skeletal problems other than 'short stature' or 'osteopenia'/'osteoporosis' by CTCAE, being classified as severe in more than one-third of them. The most common severe complication was SCFE in three survivors. Postural changes were found in six survivors, and leg length discrepancy not related to hip epiphyseolysis or scoliosis in four survivors. All these conditions may later predispose to additional musculoskeletal problems, and probably decrease physical activity in the affected survivors. Interestingly, exostoses were observed in one-fourth of the HR-NBL survivors. The increased frequency of exostoses is in line with previous studies reporting late effects in patients with HR-NBL, both with 24 and without 25 TBI as a pretreatment for HSCT.
We acknowledge that BMD as measured by DXA is affected by height, 26 and therefore high frequency of low BMD in our cohort is not a surprising finding. The use of the term 'osteopenia' (BMD Z-score o − 1.0, as currently defined in CTCAE) is not recommended in children and adolescents, and we therefore also separately report the prevalence of 'low BMD' with more strict criteria (Z-score o − 2.0), as recommended by International Society for Clinical Densitometry. 21 BMD Z-scores were lower in the HR-NBL survivors than controls, but statistical significances disappeared after height adjustment. Similarly, LS BMAD, which takes into account bone size, was comparable between the study groups. This suggests that lower BMD values are mainly explained by shorter stature in the survivors and not by actual deficit in bone density. However, neither DXA BMD Z-scores nor the bone-size corrected BMAD values measure the actual bone strength that may be compromised in the small, growth-deficient bones. The prevalence of significantly low BMD (Z-score o − 2.0 at any site) was 26% in our young adult survivors. Although this prevalence is probably overestimated because of the short stature (smaller bone volume) in many survivors, 26 this observation still necessitates careful follow-up of the affected. Furthermore, DXA is the instrument usually used in the follow-up, and this study shows that low BMD on DXA is a common finding in this patient group, and should be cautiously interpreted.
Fracture rates were similar between the study groups, and no vertebral compression fractures, typical for osteoporosis, were found on spinal MRIs. This is in line with the normal heightadjusted BMDs in the survivors. Another possible explanation for the low fracture rate (14%) in these survivors, who have poor physical performance, 27 is their reduced exercise capacity and thereby less predisposition to fractures than in active, healthy controls. There are no previous studies on fracture risk separately in HR-NBL survivors, but a large Childhood Cancer Survivor Study also found no difference in the fracture rate between long-term cancer survivors and their healthy siblings. 28 Other studies showed an overall fracture risk of 21% after childhood solid tumor 7 and a cumulative vertebral fracture rate of 26.4% during 4 years following ALL diagnosis. 13 It seems that HR-NBL treatment, not including glucocorticoids like, for example, ALL treatment, does not increase the rate of long-bone or vertebral fractures by young adulthood. Furthermore, spinal MRI did not detect any other significant abnormalities and spinal MRI is not indicated in the routine follow-up of HR-NBL patients.
Osteoporosis is a well-defined complication after radiotherapy, mainly secondary to pituitary or gonadal hormonal defects. 4 In our cohort, exposure to TBI was not associated with significantly lower BMD, although almost all TBI recipients (10/11) had required rhGH treatment, and many of them also had gonadal hormone replacement. However, TBI recipients tended to have more other severe skeletal complications. On the other hand, even local irradiation alone resulted in severe skeletal problems in some survivors, whereas combining TBI and local irradiation was not associated with worse outcome than with TBI alone, implying that other factors than dose of irradiation also affect the skeletal outcome.
In general, risk factors for SCFE include male gender, obesity, pubertal growth spurt and rhGH treatment. 29 Of our three survivors with SCFE, two were male (both with previous rhGH treatment), none was overweight, but all had received TBI and were diagnosed with SCFE at pubertal age. Our findings are in line with a previous study finding SCFE in 10/57 childhood cancer survivors (7/27 survivors of HR-NBL) exposed to TBI and rhGH treatment. 30 Another study found SCFE in 1/16 survivors after HR-NBL treatment (including TBI). 24 As for spinal malalignments, both our subjects with severe scoliosis had spinal infiltration at the disease presentation that probably was the main cause of scoliosis in these patients. They also had received local irradiation at thoracic spine and retroperitoneal areas. These findings are in agreement with Childhood Cancer Survivor Study including all patients with NBL (not only those with HR-NBL), in which severe scoliosis was more prevalent in survivors than controls. 31 Identified risk factors for scoliosis included laminectomy, thoracotomy and spinal irradiation, also consistent with our study.
Osteonecrosis has traditionally been associated with glucocorticoids in childhood cancer, and is indeed most common in ALL, where high-dose glucocorticoids are an integral part of the treatment. However, there are also a few reports of HR-NBL patients with osteonecrosis. [32] [33] [34] Both our HR-NBL survivors with osteonecrosis had received TBI, and the other had undergone kidney transplantation, that probably played the main role in the pathogenesis of osteonecrosis in that patient.
Although our national cohort includes almost all long-term survivors of HR-NBL, the total number of subjects is small and the statistical power insufficient, especially in subgroup comparisons. Moreover, our cohort was treated between 1980 and 2000, when TBI was still routinely used. Therefore, our results cannot be directly generalized to HR-NBL patients treated today. Importantly, however, also survivors who did not receive TBI were shorter than controls, and many of them presented with skeletal problems already at young adulthood. We would like to address that local irradiation (especially lumbar, thoracic and retroperitoneal area in HR-NBL) that is still routinely used may also have negative impact on growing bone.
To summarize, skeletal complications are common in young adult HR-NBL survivors treated with high-dose therapy and stem cell rescue. However, BMD does not seem to be significantly decreased when adjusted for short stature, and fracture risk is not increased. Skeletal complications can significantly impair the quality of life in HR-NBL survivors and may lead to even higher musculoskeletal morbidity with aging.
